Bicycle Therapeutics plc Overview
Pro stress-test →Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a class of medicines for diseases underserved by existing therapeutics in the United States and United Kingdom. The company develops a novel class of medicines called Bicycles, which are synthetic short peptides constrained to form two loops that stabilize their structural geometry.
Strategic Profile
Pro stress-test →The company aims to become one of the world's leading solid tumor medicines companies. Bicycle maintains strategic collaborations with major biopharmaceutical companies including Bayer, Novartis, Ionis Pharmaceuticals, and Genentech. Beyond oncology, the company is exploring applications in anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory indications.
Competitive Landscape
Pro stress-test →Bicycle competes within a crowded oncology biotech landscape with 41 identified competitors including Rhythm Pharmaceuticals and similar clinical-stage biotechs. The company's differentiation lies in its proprietary Bicycle platform technology targeting difficult-to-address tumor antigens.
Industry Context
Bicycle Therapeutics plc operates in Biopharmaceutical/Oncology.
Key facts
Founded: 2009 · Headquarters: Cambridge, UK · Revenue: $19.3M · Market cap: $557M